The number of patients with glaucoma has been increasing substantially over the years. It is already the number two cause of blindness, which leads to a growing demand for glaucoma drugs worldwide. However, traditional glaucoma prescription drugs only provide patients with a limited selection which in repetitive use can easily lose drug efficacy or even result in side effects. ITRI has been dedicated to developing new small-molecular drugs for ophthalmology, introducing novel targeted drugs for glaucoma, organizing patent portfolios, applying for clinical trials, and promoting commercialization. Adopting its unique targeted drug development technology, ITRI developed a new generation of ROCK (Rho-associated Kinase) inhibitors, which is better than other similar products in helping lower eye pressure without causing irritating side effects.
Applications & Benefits
This technology has attracted a drug manufacturer in France and spurred further collaboration between the two countries to facilitate the transformation of Taiwan’s ophthalmologic drug industry.